Corbus Pharma Cmn (CRBP) 2.93 $CRBP
Corbus Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 16, 7:19AM CDT
NORWOOD, Mass. (AP) _ Corbus Pharmaceuticals Holdings Inc. (CRBP) on Monday reported a loss of $2.9 million in its first quarter.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update
Marketwire Canada - Mon May 16, 7:13AM CDT
Company Has Three Phase 2 Studies Ongoing With Top-Line Data Expected Starting 4Q 2016; Phase 2 Clinical Study for Treatment of Systemic Lupus Erythematosus Expected to Commence 1Q 2017
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis
Marketwired - Tue Apr 12, 6:30AM CDT
Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration ("FDA" has granted approval for a 12-month open-label extension study of the ongoing Phase 2 clinical trial of Resunab for the treatment of diffuse cutaneous systemic sclerosis ("scleroderma".
CRBP: 2.93 (-0.23)
Top Stocks Investors Are Considering on Monday April 11th
ACCESSWIRE - Mon Apr 11, 11:16AM CDT
MIAMI, FL / ACCESSWIRE / April 11, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EGLE, COOL, DSCO, and CRBP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
EGLE: 0.53 (-0.03), COOL: 0.87 (unch), CRBP: 2.93 (-0.23), DSCO: 3.50 (-0.36)
Four Biotech Stocks To Consider As The Sector Breaks Out
ACCESSWIRE - Thu Apr 07, 11:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2016 / Has biotech finally bottomed? After an 8-month long bear market with biotech stocks losing over 40%, signs of a breakout are now becoming more and more obvious. All eyes are on the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) as the 50 day moving average has been overtaken since the beginning of the month.
VRX: 25.34 (+1.42), CRBP: 2.93 (-0.23), IBB: 274.25 (-4.28), SPPI: 6.98 (-0.13)
Corbus Pharmaceuticals Announces Addition of Phase 2 Clinical Protocol for Resunab Treatment of Systemic Lupus Erythematosus to FDA IND
Marketwired - Thu Mar 31, 6:30AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that a protocol amendment has been added to one of the Company's existing Investigational New Drug ("IND" Application with the U.S. Food and Drug Administration ("FDA" for a Phase 2 clinical trial of Resunab in systemic lupus erythematosus ("SLE". The amendment was filed on February 25, 2016. The addition of the SLE Phase 2 trial to the existing Resunab IND is an important step towards the initiation of the 100 patient, double-blind, placebo-controlled SLE trial which will be funded by a grant from the National Institutes of Health ("NIH" to the Feinstein Institute for Medical Research ("FIMR", Manhasset. The Company expects the trial will commence in the first quarter of 2017.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Reports 2015 Financial Results and Provides 2016 Business Update
Marketwired - Tue Mar 29, 6:30AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2015.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus
Marketwired - Mon Mar 07, 6:35AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Resunab(TM) will be tested for efficacy and safety in a Phase 2 clinical study in systemic lupus erythematosus (SLE). SLE is a prototypic autoimmune disease that can manifest with wide-ranging symptoms involving multiple organ systems.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016
Marketwired - Mon Feb 01, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016, at 8:30 a.m. EST in New York, NY.
CRBP: 2.93 (-0.23)
Smart Money Highlights Oversold Stocks in Small Cap Biotechs
ACCESSWIRE - Tue Jan 19, 10:22AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Biotech has taken a big hit so far in 2016. At the turn of the New Year, the iShares Nasdaq Biotechnology (NASDAQ:IBB) traded at $340. At the end of last week, the index closed out at $284 - a 16% decline across a two-week period. Some companies, of course, have suffered more than others. This is especially true in the development stage as investors pull capital out of riskier small caps. Not all companies warrant their declines, however, and market weakness looks to have left a few stocks oversold. At times like these, following the smart money can help us to identify the oversolds. Here are four companies with top investor backing that could be trading at a significant discount.
VRTX: 92.78 (-1.81), CRBP: 2.93 (-0.23), RPRX: 1.78 (-0.10), IBB: 274.25 (-4.28), AKBA: 8.51 (-0.15), EPZM: 12.27 (-0.72)
Corbus Pharmaceuticals to Present at Biotech Showcase(TM) on January 12, 2016
Marketwired - Tue Jan 05, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 11:00 a.m. PT in San Francisco, CA.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015
Marketwired - Mon Nov 23, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at two upcoming investor conferences in December.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Reports 2015 Third Quarter Financial Results
Marketwired - Wed Nov 11, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today its financial results for the quarter ended September 30, 2015.
CRBP: 2.93 (-0.23)
Cystic Fibrosis Conference Opens up New Treatment Possibilities
ACCESSWIRE - Mon Oct 26, 8:50AM CDT
NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Earlier this month, the Annual North American Cystic Fibrosis Conference (NACFC) took place in Arizona. Among the companies that presented were a range of public pharmas that, combined, cover the full spectrum of in-development cystic fibrosis therapies. CF is a rare disease but a big money maker, as some of the most expensive drugs in the world are CF drugs. Here's a look at each company, with a discussion on their respective approaches.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Holdings wins US FDA Fast Track development programme status & orphan drug designation for Resunab for cystic fibrosis
M2 - Wed Oct 21, 3:06AM CDT
Drug development company Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) disclosed on Tuesday the receipt of the US Food and Drug Administration's (FDA) Fast Track development programme status plus orphan drug designation for its investigational new drug Resunab for the treatment of cystic fibrosis (CF).
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
Marketwired - Tue Oct 20, 7:05AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company", a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration ("FDA" has designated as a Fast Track development program and granted Orphan Drug Designation to the Company's investigational new drug Resunab(TM) for the treatment of cystic fibrosis ("CF".
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Holdings treats fisrt subject with Resunab for cystic fibrosis
M2 - Fri Oct 16, 3:10AM CDT
Drug company Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) said on Thursday that its first subject has been dosed with its investigational new drug Resunab. for the treatment of cystic fibrosis (CF) under its Phase 2 clinical study, with expected top-line data at end of 2016.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 16, 7:19AM CDT
NORWOOD, Mass. (AP) _ Corbus Pharmaceuticals Holdings Inc. (CRBP) on Monday reported a loss of $2.9 million in its first quarter.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update
Marketwire Canada - Mon May 16, 7:13AM CDT
Company Has Three Phase 2 Studies Ongoing With Top-Line Data Expected Starting 4Q 2016; Phase 2 Clinical Study for Treatment of Systemic Lupus Erythematosus Expected to Commence 1Q 2017
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis
Marketwired - Tue Apr 12, 6:30AM CDT
Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration ("FDA" has granted approval for a 12-month open-label extension study of the ongoing Phase 2 clinical trial of Resunab for the treatment of diffuse cutaneous systemic sclerosis ("scleroderma". CRBP: 2.93 (-0.23)
Top Stocks Investors Are Considering on Monday April 11th
ACCESSWIRE - Mon Apr 11, 11:16AM CDT
MIAMI, FL / ACCESSWIRE / April 11, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EGLE, COOL, DSCO, and CRBP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
EGLE: 0.53 (-0.03), COOL: 0.87 (unch), CRBP: 2.93 (-0.23), DSCO: 3.50 (-0.36)
Four Biotech Stocks To Consider As The Sector Breaks Out
ACCESSWIRE - Thu Apr 07, 11:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2016 / Has biotech finally bottomed? After an 8-month long bear market with biotech stocks losing over 40%, signs of a breakout are now becoming more and more obvious. All eyes are on the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) as the 50 day moving average has been overtaken since the beginning of the month.
VRX: 25.34 (+1.42), CRBP: 2.93 (-0.23), IBB: 274.25 (-4.28), SPPI: 6.98 (-0.13)
Corbus Pharmaceuticals Announces Addition of Phase 2 Clinical Protocol for Resunab Treatment of Systemic Lupus Erythematosus to FDA IND
Marketwired - Thu Mar 31, 6:30AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that a protocol amendment has been added to one of the Company's existing Investigational New Drug ("IND" Application with the U.S. Food and Drug Administration ("FDA" for a Phase 2 clinical trial of Resunab in systemic lupus erythematosus ("SLE". The amendment was filed on February 25, 2016. The addition of the SLE Phase 2 trial to the existing Resunab IND is an important step towards the initiation of the 100 patient, double-blind, placebo-controlled SLE trial which will be funded by a grant from the National Institutes of Health ("NIH" to the Feinstein Institute for Medical Research ("FIMR", Manhasset. The Company expects the trial will commence in the first quarter of 2017. CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Reports 2015 Financial Results and Provides 2016 Business Update
Marketwired - Tue Mar 29, 6:30AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2015. CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus
Marketwired - Mon Mar 07, 6:35AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Resunab(TM) will be tested for efficacy and safety in a Phase 2 clinical study in systemic lupus erythematosus (SLE). SLE is a prototypic autoimmune disease that can manifest with wide-ranging symptoms involving multiple organ systems. CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016
Marketwired - Mon Feb 01, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016, at 8:30 a.m. EST in New York, NY. CRBP: 2.93 (-0.23)
Smart Money Highlights Oversold Stocks in Small Cap Biotechs
ACCESSWIRE - Tue Jan 19, 10:22AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Biotech has taken a big hit so far in 2016. At the turn of the New Year, the iShares Nasdaq Biotechnology (NASDAQ:IBB) traded at $340. At the end of last week, the index closed out at $284 - a 16% decline across a two-week period. Some companies, of course, have suffered more than others. This is especially true in the development stage as investors pull capital out of riskier small caps. Not all companies warrant their declines, however, and market weakness looks to have left a few stocks oversold. At times like these, following the smart money can help us to identify the oversolds. Here are four companies with top investor backing that could be trading at a significant discount.
VRTX: 92.78 (-1.81), CRBP: 2.93 (-0.23), RPRX: 1.78 (-0.10), IBB: 274.25 (-4.28), AKBA: 8.51 (-0.15), EPZM: 12.27 (-0.72)
Corbus Pharmaceuticals to Present at Biotech Showcase(TM) on January 12, 2016
Marketwired - Tue Jan 05, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 11:00 a.m. PT in San Francisco, CA. CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015
Marketwired - Mon Nov 23, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at two upcoming investor conferences in December. CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Reports 2015 Third Quarter Financial Results
Marketwired - Wed Nov 11, 6:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today its financial results for the quarter ended September 30, 2015. CRBP: 2.93 (-0.23)
Cystic Fibrosis Conference Opens up New Treatment Possibilities
ACCESSWIRE - Mon Oct 26, 8:50AM CDT
NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Earlier this month, the Annual North American Cystic Fibrosis Conference (NACFC) took place in Arizona. Among the companies that presented were a range of public pharmas that, combined, cover the full spectrum of in-development cystic fibrosis therapies. CF is a rare disease but a big money maker, as some of the most expensive drugs in the world are CF drugs. Here's a look at each company, with a discussion on their respective approaches.
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Holdings wins US FDA Fast Track development programme status & orphan drug designation for Resunab for cystic fibrosis
M2 - Wed Oct 21, 3:06AM CDT
Drug development company Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) disclosed on Tuesday the receipt of the US Food and Drug Administration's (FDA) Fast Track development programme status plus orphan drug designation for its investigational new drug Resunab for the treatment of cystic fibrosis (CF).
CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
Marketwired - Tue Oct 20, 7:05AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"
, a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration ("FDA" has designated as a Fast Track development program and granted Orphan Drug Designation to the Company's investigational new drug Resunab(TM) for the treatment of cystic fibrosis ("CF". CRBP: 2.93 (-0.23)
Corbus Pharmaceuticals Holdings treats fisrt subject with Resunab for cystic fibrosis
M2 - Fri Oct 16, 3:10AM CDT
Drug company Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) said on Thursday that its first subject has been dosed with its investigational new drug Resunab. for the treatment of cystic fibrosis (CF) under its Phase 2 clinical study, with expected top-line data at end of 2016.
CRBP: 2.93 (-0.23)
